Next, when we treated genetically manipulated cells with Oxaliplatin and 5-Fu, LOXL3 depletion greatly sensitized liver cancer cells to these drugs, whereas depletion of other members of the LOX family had no significant effects on chemotherapy resistance (Fig. 1a, Supplementary Fig. 1c). This evidence concerns the gene LOXL3 and liver cancer.